Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects

Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects

Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell variants, medullary TC (MTC), anaplastic TC (ATC), and poorly differentiated TC (PDTC). The standard of care in DTC consists of...

Full description

Bibliographic Details
Main Authors: Ivana Puliafito, Francesca Esposito, Angela Prestifilippo, Stefania Marchisotta, Dorotea Sciacca, Maria Paola Vitale, Dario Giuffrida
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Endocrinology
Subjects:
thyroid cancer
target therapy
adverse events
tyrosine kinase inhibitors
multikinase inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.860671/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.860671/full

Similar Items